Viking Therapeutics Highlights Clinical Momentum Ahead of Key Investor Conferences

Upcoming Miami Appearances Center on Growing Pipeline

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharma company focused on metabolic and endocrine disorders, is set to showcase its latest research at two major investor gatherings this week: the Leerink Partners Global Healthcare Conference (March 8-11) and the Jefferies Biotech on the Beach Summit (March 10-11), both hosted in Miami. Management will participate in one-on-one investor meetings and present a fireside chat, live-streamed for broader investor access.

Key Conference Details for Investors

A live webcast of the Leerink fireside chat will be available on the Viking Therapeutics website, with a replay provided after the event.

Late-Stage VK2735 and VK2809 Programs Show Clinical Promise

Viking has been building momentum with its lead clinical assets. VK2735, a novel dual GLP-1/GIP agonist for metabolic disorders, is being evaluated in a Phase 3 obesity program featuring two pivotal trials (VANQUISH-1 and VANQUISH-2). Results from earlier-phase studies confirmed that VK2735 had a highly favorable safety profile and encouraging clinical benefits. The company is also progressing an oral version of VK2735 for obesity, targeting a significant and growing patient population.

Meanwhile, VK2809—an oral, selective thyroid hormone receptor beta agonist—continues to demonstrate its potential to reshape how NASH (non-alcoholic steatohepatitis) and lipid metabolism conditions are treated. In Phase 2b, VK2809 hit both primary and secondary endpoints for biopsy-confirmed NASH and fibrosis. Additionally, a Phase 2a trial in NAFLD (non-alcoholic fatty liver disease) with high LDL-C showed patients on VK2809 had statistically significant reductions in both LDL-C and liver fat, outperforming placebo.

Expanding into Rare Disease and Multi-Target Approaches

The company’s newest research efforts address both prevalent and rare metabolic diseases. Viking’s internally developed DACRAs (dual amylin and calcitonin receptor agonists) target obesity, while VK0214, an oral THR-beta agonist, is in the works for X-linked adrenoleukodystrophy (X-ALD)—a very rare and serious neurological disease. Early Phase 1b data in the AMN form of X-ALD show VK0214 is well tolerated, with patients achieving meaningful drops in disease-causing very long-chain fatty acids.

Investor Events Could Reveal More on Growth Trajectory

Viking’s upcoming investor presentations provide an opportunity for deeper insight into its growing pipeline and commercial strategy. Key discussion points are likely to include clinical progress, regulatory strategy, and how the company plans to leverage its multi-asset portfolio across distinct metabolic and rare disease indications.

What to Watch For Next

For stakeholders, the next phase of data on VK2735 in obesity and VK2809 in NASH and NAFLD will be particularly important. Updates from Miami’s investor conferences could provide further signals about the company’s direction, partnerships, and future catalysts. Investors and analysts may want to tune into the Leerink chat for any new color on upcoming clinical milestones or commercial opportunities.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI